DOCSLIB.ORG

Antibacterial Antibiotic Antifungal Antiparasitic Antiviral

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibacterial Antibiotic Antifungal Antiparasitic Antiviral All-In-One Flooring Solutions: Antibacterial Antibiotic Antifungal Antiparasitic Antiviral What are antimicrobials? The Dex-O-Cide Difference: Antimicrobials provide a much broader range Based on the active agent N-butyl-1, 2- benzisothiazo- lin-3-one (BBIT), it is specially formulated to protect of protection than antibacterials. While anti- flooring in tough and demanding environments, bacterials kill a range of bacteria, antimocro- especially those exposed to high levels of moisture, UV bials go further, acting also as an antibiotic, light, or unsanitary conditions. The silver ion producing additive is integrated throughout the floor coating matrix antifungal, antiparasitic and antiviral agent. - not just the surface, so scratches and other points of Antimicrobials kill, and prevent the growth and wear do not create a place where pathogens can create spread of, dangerous microscopic organisms a home to grow and spread. The antimicrobial does not wash or wear away, preserving the protective proper- including bacteria, viruses, yeast, fungi, proto- ties for the life of the floor. zoa and some algae. Bacterial Resistance: Dex-O-Cide Standards: How antimicrobials work: CoV (Covid19) • • ISO 22196 SARS • • ISO JIS 222801 Salmonella Typhi • Instead of using chemicals, Dex-O-Cide • FSANZ Staphylococcus Aureus • Antibacterial Flooring leverages the all- Streptococcus Pygenes • natural power of silver ions to penetrate cell MRSA • membranes of bacteria and kill the pathogen. E-coli • Listeria Welshimeri • Common bacterium have no defense against Pseudomonas Aeruginosa • it. The system works continually, giving you Campila Bacta • added protection between cleaning cycles. C.difficile • Proteus Vulgaris • Entercoccus Faecalis • Dex-O-Tex Flooring Systems: • Décor Flor • Tek-Crete • Terracolor • Quick-Glaze • HPT • Aero-Flor • Posi-Tred • Cheminert Advantages: • Works continually • All-natural solution uses silver ions instead of chemicals • Added protection between cleaning cycles • Eliminates up to 99.9% of bacteria • Homogeniously distributed throughout floor matrix - not just the surface • Seamless and easy to clean • Impervious, non-porous • Durable and hard wearing • Chemical, heat and impact resistant • Provides broader array of protection than antibacterials • Withstands high UV exposure • Suitable for exterior or interior use • Helps control odors generated by microbe action Applications: Food Processing Beverage Processing Pharmaceutical Manufacturing Chemical Processing Pulp & Paper Plants Hospitals & Clinics Laboratories Commercial Kitchens Restaurants & Cafeterias Locker Rooms Public Restrooms Manufacturing Facilities Fire, Rescue & Public Safety Facilities Technology Centers Dex-O-Cide Antimicrobial can be integrated with an array of Dex-O-Tex flooring systems including Tek-Crete, Decor Flor, Posi-Tred and Cheminert. Learn more about these flooring systems at Dex-O-Tex.com, or consult a Dex-O-Tex Technician to find the best flooring system for your application. INDUSTRY ASSOCIATIONS dexotex.com • [email protected] • (310) 886-9100 West Coast • (908) 245-2800 East Coast • (210) 888-0449 Texas.
Load more

Recommended publications
  • Skin Probiotics ACCELERATING INNOVATION
    ACCELERATING INNOVATION James Madison University technologies are available for licensing through its nonprofit affiliate, James Madison Innovations, Inc. Skin Probiotics Inventors: Reid Harris and Kevin Minbiole Department: Biology and Chemistry Overview Research Funding and Source: National Science Foundation James Madison University inventors have filed a patent Years of Development: 4 years application on a helpful bacterium that could potentially be Technology Readiness: Research Development used as a therapy for human skin fungus such as athlete’s foot. Patent Status: U.S. patent pending 20110002891 The JMU inventors have developed a potential process to Contact: Mary Lou Bourne, Director of Technology Transfer deliver a helpful microbe, Janthinobacterium Lividum to the James Madison University skin using a pharmaceutically acceptable carrier. The microbe Phone: (540)568-2865 E-mail: [email protected] has been shown to suppress bacterial and fungal growth on animals and in lab demonstrations. Tech Transfer and Business Model Infections can be a problem for a wide array of hosts. For JMI is interested in identifying an existing company or example, there are a variety of infections, such as bacterial, entrepreneur interested in commercializing the technology viral and/or fungal infections, that affect a large percentage of either under an exclusive or a non-exclusive license. A the human population. Tricophyton rubrum, the fungus that small company or entrepreneur could further develop the causes athlete’s foot, is responsible for approximately 46% to technology, possibly using SBIR or STTR funding. 72% of cutaneous and nail mycoses worldwide. Onychomycosis, a common and persistent fungal infection, is Market and Competition In 2008, the U.S.
    [Show full text]
  • Natural Products As Potential Antiparasitic Drugs
    Natural Products as potential antiparasitic drugs OLIVER KAYSER1, ALBRECHT F. KIDERLEN2, SIMON L. CROFT3 1Freie Universität Berlin Institut für Pharmazie, Pharmazeutische Biotechnologie Kelchstraße 31, 12169 Berlin, Germany 2Robert Koch-Institut Nordufer 20 13353 Berlin, Germany 3London School of Hygiene and Tropical Medicine Department of Infectious and Tropical Diseases Keppel Street London, WC1E 7HT, United Kingdom ABSTRACT: Pharmaceutical research in natural products represents a major strategy for discovering and developing new drugs. The use of medicinal plants for the treatment of parasitic diseases is well known and documented since ancient times e.g. by the use of Cinchona succiruba (Rubiaceae) as an antimalarial. This chapter provides a comprehensive review of the latest results in the field of antiparasitic drug development from biologic sources (plants, bacteria, fungi and marine organisms) focussing on the treatment of protozoal infections (Plasmodium, Leishmania, Trypanosoma spp.). The status of validated in vitro and in vivo assays is reviewed, discussing their different features, problems and limitations. Because of the high number of natural products tested against the aforesaid protozoa in the last years, we limit the discussion to lignans, phenolics, terpenoids, and alkaloids as defined natural product classes. The review also covers essential research topics of recent publications on specific natural products (e.g. licochalcone A, benzyl- and naphthylisoquinoline alkaloids, and artemisinin) and gives an outlook to semi- synthetic approaches of drugs already introduced in clinics or in clinical trial studies. 1. INTRODUCTION The fascination of natural products, mostly as used as a preparation from a plant with known medicinal properties, goes back to ancient times. The discovery of pure compounds as active principles in plants was first described at the beginning of the 19th century, and the art of exploiting natural products has become part of the molecular sciences.
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • Topical Corticosteroids and Fungal Keratitis: a Review of the Literature and Case Series
    Journal of Clinical Medicine Review Topical Corticosteroids and Fungal Keratitis: A Review of the Literature and Case Series Karl Anders Knutsson 1,*, Alfonso Iovieno 2,3, Stanislav Matuska 1, Luigi Fontana 2 and Paolo Rama 1 1 Cornea and Ocular Surface Unit, San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] (S.M.); [email protected] (P.R.) 2 Arcispedale Santa Maria Nuova—IRCCS, 42123 Reggio Emilia, Italy; [email protected] (A.I.); [email protected] (L.F.) 3 Department of Ophthalmology, University of British Columbia, Vancouver, BC V6T 1Z, Canada * Correspondence: [email protected] or [email protected]; Tel./Fax: +39-022-6432-648 Abstract: The management of fungal keratitis is complex since signs and symptoms are subtle and ocular inflammation is minimal in the preliminary stages of infection. Initial misdiagnosis of the condition and consequent management of inflammation with corticosteroids is a frequent occurrence. Topical steroid use is considered to be a principal factor for development of fungal keratitis. In this review, we assess the studies that have reported outcomes of fungal keratitis in patients receiving steroids prior to diagnosis. We also assess the possible rebound effect present when steroids are abruptly discontinued and the clinical characteristics of three patients in this particular clinical scenario. Previous reports and the three clinical descriptions presented suggest that in fungal keratitis, discontinuing topical steroids can induce worsening of clinical signs. In these cases, we recommend to slowly taper steroids and continue or commence appropriate antifungal therapy. Citation: Knutsson, K.A.; Iovieno, A.; Keywords: fungal keratitis; topical corticosteroids; topical steroids; rebound effect Matuska, S.; Fontana, L.; Rama, P.
    [Show full text]
  • Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity
    molecules Review Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity Valery M. Dembitsky 1,2,*, Ekaterina Ermolenko 2, Nick Savidov 1, Tatyana A. Gloriozova 3 and Vladimir V. Poroikov 3 1 Centre for Applied Research, Innovation and Entrepreneurship, Lethbridge College, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada; [email protected] 2 A.V. Zhirmunsky National Scientific Center of Marine Biology, 17 Palchevsky Str., 690041 Vladivostok, Russia; [email protected] 3 Institute of Biomedical Chemistry, 10 Pogodinskaya Str., 119121 Moscow, Russia; [email protected] (T.A.G.); [email protected] (V.V.P.) * Correspondence: [email protected]; Tel.: +1-403-320-3202 (ext. 5463); Fax: +1-888-858-8517 Abstract: Polycyclic endoperoxides are rare natural metabolites found and isolated in plants, fungi, and marine invertebrates. The purpose of this review is a comparative analysis of the pharmacological potential of these natural products. According to PASS (Prediction of Activity Spectra for Substances) estimates, they are more likely to exhibit antiprotozoal and antitumor properties. Some of them are now widely used in clinical medicine. All polycyclic endoperoxides presented in this article demonstrate antiprotozoal activity and can be divided into three groups. The third group includes endoperoxides, which show weak antiprotozoal activity with a reliability of up to 70%, and this group includes only 1.1% of metabolites. The second group includes the largest number of endoperoxides, Citation: Dembitsky, V.M.; which are 65% and show average antiprotozoal activity with a confidence level of 70 to 90%. Lastly, Ermolenko, E.; Savidov, N.; the third group includes endoperoxides, which are 33.9% and show strong antiprotozoal activity with Gloriozova, T.A.; Poroikov, V.V.
    [Show full text]
  • The Role of Antiparasitc Drugs and Steroids in Covid-19 Treatment
    Research, Society and Development, v. 10, n. 8, e39510817300, 2021 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v10i8.17300 The role of antiparasitc drugs and steroids in Covid-19 treatment O papel das drogas antiparasitárias e corticóides no tratamento da Covid-19 El papel de los antiparasitos y los esteroides en el tratamiento del Covid-19 Received: 06/17/2021 | Reviewed: 06/25/2021 | Accept: 07/03/2021 | Published: 07/14/2021 Luciano Barreto Filho ORCID: https://orcid.org/0000-0002-1508-4812 Faculdade de Odontologida do Recife, Brazil E-mail: [email protected] Paulo Reis Melo Júnior ORCID: https://orcid.org/0000-0001-9926-5348 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Guilherme Marinho Sampaio ORCID: https://orcid.org/0000-0003-4441-7601 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Gabriel Henrique Queiroz Oliveira ORCID:https://orcid.org/0000-0002-7795-3964 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Hadassa Fonsêca Da Silva ORCID: https://orcid.org/0000-0002-9432-9522 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Sandra Sayão Maia ORCID: https://orcid.org/0000-0001-6808-9775 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Abstract Background: COVID-19 has emerged as a pandemic that spread throughout the world in less than 6 months, leaving hundred thousand deaths behind. Surprisingly, old drug arsenal has now been applied as an option of treatment. Objective: The aim of this article was to accomplish a literature review concerning the antiparasitic chloroquine, ivermectin, nitazoxanide; as well as glucocorticoids as possible therapeutic agents to be applied in patients with COVID-19 in Brazilian hospitals.
    [Show full text]
  • Essential Oils and Bioactive Components Against Arthritis: a Novel Perspective on Their Therapeutic Potential
    plants Review Essential Oils and Bioactive Components against Arthritis: A Novel Perspective on Their Therapeutic Potential Mariangela Marrelli * , Valentina Amodeo, Maria Rosaria Perri, Filomena Conforti y and Giancarlo Statti y Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; [email protected] (V.A.); [email protected] (M.R.P.); fi[email protected] (F.C.); [email protected] (G.S.) * Correspondence: [email protected]; Tel.: +39-0984-493168; Fax: +39-0984-493107 These authors jointly supervised and contributed equally to this work. y Received: 18 August 2020; Accepted: 21 September 2020; Published: 23 September 2020 Abstract: Essential oils (EOs) are known to possess a number of beneficial properties. Their antimicrobial, anti-inflammatory, antioxidant, antidiabetic, and cancer-preventing activities have been extensively reported. Due to their wide use as food preservers and additives, as well as their use in agriculture, perfumes, and make-up products, these complex mixtures of volatile compounds have gained importance from a commercial point of view, not only in the pharmaceutical industry, but also in agronomic, food, cosmetic, and perfume industries. An analysis of the recent scientific literature allowed us to highlight the presence of an increasing number of studies on the potential antiarthritic properties of EOs and their main constituents, which seems to suggest a new interesting potential therapeutic application. The aim of this review is to examine the current knowledge on the beneficial effects of essential oils in the treatment of arthritic diseases, providing an overview of the reports on the in vivo and in vitro effects of EOs.
    [Show full text]
  • Review Rheumatological Patients Undergoing Immunosuppressive
    Review Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: a review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections S. Fabiani and F. Bruschi Department of Translational Research ABSTRACT Conclusions. Considering parasitic in- and New Technologies in Medicine and Objective. Nowadays, several po- fections as emerging and potentially se- Surgery, School of Infectious Diseases, tent immunosuppressive drugs are rious in their evolution, additional strat- Università di Pisa, Pisa, Italy available for patients with rheumato- egies for the prevention, careful screen- Silvia Fabiani, MD logic disorders. In general, these treat- ing and follow-up, with a high level of Fabrizio Bruschi, MD ments are acceptably well tolerated. suspicion, identification, and pre-emp- Please address correspondence to: Nevertheless, in patients with rheu- tive therapy are necessary in candidate Fabrizio Bruschi, matic diseases, who are taking immu- patients for biological agents. Scuola Medica, Via Roma 55, nosuppressive drugs, an increased risk 56126 Pisa, Italy. of bacterial, viral and fungal, as well Introduction E-mail: [email protected] as parasitic infections, exists. Rationale Received on October 14, 2013; accepted Methods. We have reviewed literature, Immunosuppressive drugs, other than in revised form on February 18, 2014. on PubMed library, on the topic “par- corticosteroids (CS), are used in the Clin Exp Rheumatol 2014; 32: 587-596. asitic infections in rheumatic disease treatment of various rheumatologic con- © Copyright CLINICAL AND patients treated with immunosuppres- ditions to induce or maintain a remis- EXPERIMENTAL RHEUMATOLOGY 2014. sive drugs, including biological thera- sion, to reduce the frequency of flare pies”.
    [Show full text]
  • POS0555 the NATURAL COURSE of RHEUMATOID ARTHRITIS- Medications for RA Or for Comorbidities Including Adverse Events (Aes)
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.2810 on 19 May 2021. Downloaded from 512 Scientific Abstracts Methods: We used a large Japanese administrative claims database con- Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., and Takeda structed by the Japan Medical Data Center (JMDC)2. Patients with the Inter- Pharmaceutical Co., Ltd., Consultant of: AbbVie GK, Bristol-Myers Squibb K.K., national Classification of Diseases 10th revision (ICD-10) codes for RA were Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Gilead Sciences enrolled at the first DMARDs prescription after no DMARDs prescription period Inc., Grant/research support from: AbbVie GK, and Asahi Kasei Corp., Astellas for 6-months (index date) in the period from 1/1/2012 to 12/31/2017. Patients who Pharma Inc., Ayumi Pharmaceutical Corporation, Bristol-Myers Squibb K.K., were observable for 12 months after the index date as a follow-up period were Chugai Pharmaceutical Co., Ltd. Daiichi-Sankyo, Inc., Eisai Co., Ltd., Mitsubishi included. Patients treated with CSs within the follow-up period were compared Tanabe Pharma Corporation., Nippon Kayaku Co., Ltd., Taisho Pharmaceutical with those without them (CS and non-CS group). The primary endpoint was Co., Ltd., and Takeda Pharmaceutical Co., Ltd. mean medical cost per patient in the 12-month follow-up period. The secondary DOI: 10.1136/annrheumdis-2021-eular.2805 endpoints were costs for drugs, treatments, and materials and the proportions of patients using the subcategories of each resource. Drugs were divided into POS0555 THE NATURAL COURSE OF RHEUMATOID ARTHRITIS- medications for RA or for comorbidities including adverse events (AEs).
    [Show full text]
  • Antiparasitic, Antibacterial, and Antifungal Activities Derived from a Terminalia Catappa Solution Against Some Tilapia (Oreochromis Niloticus) Pathogens
    Antiparasitic, Antibacterial, and Antifungal Activities Derived from a Terminalia catappa Solution against Some Tilapia (Oreochromis niloticus) Pathogens C. Chitmanat, K. Tongdonmuan, P. Khanom, P. Pachontis and W. Nunsong Department of Fisheries Technology College of Agricultural Production Maejo University, Chiang Mai, 50290 Thailand Keywords: antibacterial activity, antiparasitic activity, antifungal activity, Terminalia catappa, medicinal plant, tilapia Abstract Tilapia, Oreochromis niloticus, is one of the most economically important fishery products of Thailand with export viability. Unfortunately, disease losses cause a major problem in the production of farmed tilapia. Most farmers have been using chemicals and antibiotics to treat fish pathogens which leads to the creation of antibiotic resistant pathogens and undesired residues in the fish and in the environment. Food safety is currently a great concern worldwide and Thailand’s inspectors are now finding antibiotic residues in exported fish products. The purpose of the present research is to apply the Indian almond, Terminalia catappa, as an alternative to the use of chemicals and antibiotics in the aquaculture industry. Dried leaves of Indian almond were ground and dissolved in water. A variety of concentrations of this solution were used to determine resulting activities against tilapia pathogens. The results indicated that Trichodina, fish ectoparasites, were eradicated at 800 ppm. The growth of two strains of Aeromonas hydrophila was also inhibited at a concentration of 0.5 mg/ml Indian almond leaves upward. In addition, this solution can reduce the fungal infection in tilapia eggs. Research is underway to determine the toxicity of this solution, if any, on tilapia and the isolation of the active ingredients in the Indian almond for fish pathogen treatment.
    [Show full text]
  • Itraconazole Inhibits AKT/Mtor Signaling and Proliferation in Endometrial Cancer Cells
    ANTICANCER RESEARCH 37 : 515-520 (2017) doi:10.21873/anticanres.11343 Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells HIROSHI TSUBAMOTO 1,2 , KAYO INOUE 1, KAZUKO SAKATA 1, TOMOKO UEDA 1, RYU TAKEYAMA 1, HIROAKI SHIBAHARA 1 and TAKASHI SONODA 2 1Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan; 2Department of Medical Oncology, Meiwa Hospital, Nishinomiya, Japan Abstract. Background: Itraconazole is a common antifungal functions by blocking ergosterol synthesis in fungal cell agent that has demonstrated anticancer activity in preclinical membrane. Itraconazole has been repositioned as an anticancer and clinical studies. This study investigated whether agent in both pre-clinical and clinical studies, and was found itraconazole exerts this effect in endometrial cancer (EC) cells. to reverse P-glycoprotein-mediated chemoresistance of cancer Materials and Methods: Cell viability was evaluated with the cells (4, 5) and inhibit angiogenesis (6) as well as Hedgehog 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (7, 8) and AKT/mammalian target of rapamycin (mTOR) (9, assay, and gene and protein expression were assessed by 10) signaling, which are associated with dysregulation of microarray analysis and immunoblotting, respectively, in five intracellular cholesterol transport (9, 11). Recent studies have EC cell lines. Results: Itraconazole-suppressed proliferation of also reported the induction of autophagy and inhibition of AN3-CA, HEC-1A and Ishikawa cells (p<0.05) but not of lymphangiogenesis by itraconazole (11, 12). HEC-50B or SNG-II cells. Itraconazole did not suppress GLI1 We have been treating patients with refractory solid or GLI2 transcription but did inhibit the expression of tumours by combination itraconazole chemotherapy since mammalian target of rapamycin (mTOR) signaling components 2008.
    [Show full text]